01-20-2006, 12:20 AM
This is a piece of spam email I got today at work. Not directly related to autism but sobering reading. UGH!
The schizophrenia world market generated total revenues of nearly $12 billion in 2004. The market is growing now. Are you capitalising on this market? Did you benefit from the strong growth in 2003 and 2004? With almost all the leading drugs also approved for treating aspects of bipolar disorder, the opportunities for drugs in this market are increasing rapidly. Dementia, autism, aggression, post-traumatic stress disorder and severe depression - the unapproved (off-label) uses for some of the drugs offer improved sales options. Ensure you benefit today by reading visiongain's unique report.
This market report delivers to you exactly how schizophrenia treatments will develop this decade. You will receive analytical forecasts of the market from 2005 to 2010. This executive report presents you with financial forecasting, SWOT analysis and perceptual mapping applied specifically to the schizophrenia drug market.
In particular, the report concentrates on the following areas:
The current state of the market for atypical antipsychotic drugs in the treatment of schizophrenia
Drivers and opportunities in the schizophrenia market
Restraints and threats in the schizophrenia market
How the schizophrenia market is likely to grow between 2005 and 2010
Prospects for the current market leading drugs between 2005 and 2010
The potential for generics manufacturers to penetrate the market further
A breakdown of the schizophrenia market by country and region
A discussion of unmet needs in the schizophrenia market
Detailed information on pipeline products and line extensions in this market, with an analysis of the prospects for those agents
The schizophrenia market is dominated by 6 drugs marketed by 8 companies:
Eli Lilly's Zyprexa
Johnson & Johnson's Risperdal
AstraZeneca and Fujisawa Pharmaceutical's Seroquel
Bristol-Myers Squibb and Otsuka Pharmaceutical's Abilify
Pfizer's Geodon
Novartis' Clozaril/Leponex
With continued prospects for high revenue generation and market growth, this market demands your attention. Nevertheless, the schizophrenia market is facing great challenges in terms of clinical performance, competition, regulatory restraints and legal challenges. Given the complexity of schizophrenia, continued investment in research and development of improved treatments is required, as well as research into the causes and mechanisms of the disorder - this is costly and time-consuming. However recent developments in both the pharmaceutical industry and the public sector provide scope for optimism - understand these crucial issues today.
Why You Should Buy This Report
Visiongain's report pays particular attention to revenues, growth rates and market shares for schizophrenia treatments. It discusses the forces that influence the schizophrenia market, especially its competitive characteristics, drivers and restraints. With unique insight the report offers the strengths, weaknesses, opportunities and threats of individual products.
A key chapter forecasts the performance of the current leading drugs until 2010. Visiongain's in-house analytical assessment of future revenues, growth rates and relative market shares are available to you in one easy to read format. Various quantitative and qualitative methods are used, with the relevant issues discussed fully for you.
Plus, the report also includes a breakdown of the world market for atypical antipsychotic drugs into countries and regions, including relevant statistics on spending across the world. Importantly, the report discusses pipeline developments for treating schizophrenia comprehensively in the future. The market appears to be entering an exciting new phase, with both established market leaders and potential new entrants having products in mid-to-late stage development - you should be part of this market.
Table of Contents
1. Executive Summary
2. Introduction to Schizophrenia
2.1 Symptoms of the Condition
2.2 Diagnosis of Schizophrenia
2.3 Links with Other Disorders
2.4 Epidemiology of Schizophrenia
2.5 Causes and Physiological Characteristics of Schizophrenia
2.6 The Treatment of Schizophrenia by Drugs
2.7 Other Aspects of Treating or Managing Schizophrenia
2.8 Mechanisms of the Newer Therapeutic Agents - The Atypical Antipsychotics
2.9 An Overview of How the Typical Antipsychotic Drugs Differ from the Atypical Antipsychotics
2.10 Adherence by Schizophrenics is Often Low
2.11 Off-Label Prescription Extending Approved Indications for Atypical Antipsychotic Drugs
2.12 The Prospects for Patients
3. The World Market 2003-2004 for Anti-Schizophrenic Drugs
3.1 The Market for Treating Schizophrenia Contains Three Major Blockbusters
3.2. Eli Lilly's Zyprexa Led the Schizophrenia Market in 2004
3.3 The Other Atypical Antipsychotics Displayed Healthy Revenues in 2004
3.3.1 Johnson & Johnson's Risperdal - Second Largest Revenue Generator in Market
3.3.2 AstraZeneca's Seroquel - Maintaining a Strong Position
3.3.3 Otsuka Pharmaceutical & Bristol-Myers Squibb's Abilify Shows Enormous Potential
3.3.4 Pfizer's Geodon - A Promising Start
3.3.5 Novartis' Clozaril/Leponex - The Pioneering Atypical Antipsychotic
3.4 The Atypical Antipsychotic Drugs Still Suffer from Concerns Over Side Effects
3.5 Patent Expiry Among the Leading Schizophrenia Drugs - An Increasing Threat 2005-2010
3.6 Comparative Studies on Schizophrenia Drugs - a Blessing or a Curse for the Market Leaders?
4. An Analysis of Factors that Influence the Schizophrenia Market
4.1 SWOT Analysis of the Schizophrenia Market?
4.2 What Are the Main Drivers, Strengths and Opportunities in the Schizophrenia Market?
4.3 Principal Drivers in the Schizophrenia Market
4.4 The Atypical Antipsychotics Constitute a Large, High-Growth Market
4.5 Maintaining High Revenue Generation in Spite of Challenges
4.6 There is Scope for Greater Penetration into Related Markets
4.7 Advances in Technology Likely to Bring Benefits to the Market
4.8 Comparative Studies - a Two Edged Sword
4.9 The Principal Restraints in the Schizophrenia Market
4.10 Risk of Diabetes and Other Serious Side Effects with the Atypical Antipsychotic Drugs
4.11 Concerns Over the High Price of the Treatments - Who Yields the Power?
4.12 A Discussion of Generic Drugs in This Market - How Great is Their Threat?
5. The World Market for Schizophrenia Treatments 2004-2010
5.1 World Revenue from 2004 to 2010 - A Maturing Market with High Revenue Potential
5.2 Zyprexa to Retain Market Leadership Despite Pressures
5.3 Risperdal - Strong Revenue Potential Despite Side Effects and Generics Threat
5.4 Will Seroquel Remain a Strong Contender?
5.5 Can Abilify Build upon Early Promise?
5.6 Geodon has Growth Potential Despite Generics Threat
5.7 Can Clozaril ''Re-Invent'' Itself to Offset Decline?
6. A Geographical Breakdown of the World Market
6.1 Schizophrenia - A World Market Led by US Sales
6.2 The US Leads the World in Healthcare Spending
6.3 The US and Europe are the Most Important Markets for Schizophrenia Treatments
7. An Analysis of Unmet Needs in the Schizophrenia Market
7.1 Analysing Efficacy, Safety and Tolerability in the Schizophrenia Market via Perceptual Mapping
7.2 How Much Scope is There to Improve Efficacy in Schizophrenia Drugs?
7.3 How Much Scope is There to Improve Safety and Tolerability in Schizophrenia Drugs?
7.4 Pricing of the Atypical Antipsychotics - Close Scrutiny by Medical Authorities and Concern Amongst Patients' Groups
7.5 Screening and Diagnosis by Healthcare Services is a Necessary Prerequisite for Market Growth
7.6 Direct Advertising - An Opportunity to Educate Consumers but also a Source of Controversy
8. Pipeline Drugs for Schizophrenia
8.1 Agents in Preclinical Development
8.1.1 BL-1020
8.1.2 Other Agents in Preclinical Development
8.2 Agents in Phase I of Clinical Development
8.2.1 TC-1827
8.2.2 Other Agents in Phase I Clinical Development
8.3 Agents in Phase II of Clinical Development
8.3.1 Talnetant
8.3.2 SM13496 (Lurasidone)
8.3.3 ACP-103
8.3.4 ACP-104
8.3.5 Org 24448
8.3.6 Other Agents in Phase II Clinical Development
8.4 Agents in Phase III of Clinical Development
8.4.1 Iloperidone
8.4.2 Asenapine
8.4.3 Bifeprunox
8.4.4 Blonanserin
8.4.5 Paliperidone
8.4.6 Osanetant
8.4.7 Other Agents in Phase III Clinical Development
8.5 Treatments Recently Approved for Treating Schizophrenia
8.5.1 Serdolect
8.6 The Further Development of Existing Treatments for Schizophrenia
8.6.1 A Line Extension of AstraZeneca's Seroquel
8.7 An Overall Assessment of Pipeline Developments for the Schizophrenia Market
9 Conclusions of this Market Study
Tables Included in this Report
Table 1.1 Market Leading Drugs for Treating Schizophrenia
Table 2.1 First Generation Antipsychotic Drugs for Treating Schizophrenia (the Typical Antipsychotics)
Table 2.2 Mild and Serious Side Effects of First Generation Antipsychotics
Table 2.3 Second Generation Antipsychotic Drugs for Treating Schizophrenia (the Atypical Antipsychotics)
Table 2.4 Mild and Serious Side Effects of Second Generation Antipsychotics
Table 3.1 Best-Selling Drugs in the Therapeutic Category Psychotherapeutic Agents in 2004
Table 3.2 The Leading Drugs for Treating Schizophrenia: Indications and Modes of Action
Table 3.3 The Leading Drugs for Treating Schizophrenia: 2004 Revenues and Growth Rates
Table 3.4 Market Shares for the Leading Schizophrenia Drugs in 2004
Table 3.5 Side Effects and Potential Risks Associated with Leading Drugs for Schizophrenia
Table 3.6 Patent Expiry in the Market Leading Drugs for Schizophrenia
Table 4.1 Side Effect Profiles of the Second Generation Antipsychotic Drugs
Table 5.1 World Revenues ($m) for the Leading Schizophrenia Drugs 2004 to 2010
Table 5.2 Compound Annual Growth Rates (CAGRs) for the Leading Schizophrenia Drugs
Table 5.3 World Revenues ($m) of Seroquel and Abilify Only, 2004-2010
Table 5.4 World Revenues for Schizophrenia Treatments, 2004 and 2010 Compared
Table 5.5 Market Share (%) for Schizophrenia Drugs, 2004 and 2010 Compared
Table 6.1 A Global Breakdown of the Schizophrenia Market by Country and Region, 2004
Table 6.2 Total Health Spending ($) and Drug Expenditure per Patient in Major Countries in 2002
Table 6.3 Annual Average Growth Rates (%) in GDP, Total and Public Health Expenditure of Principal Countries, 1997-2002
Table 7.1 Efficacy and Side Effect Profiles of the Leading Schizophrenia Drugs
Table 7.2 Prices of The Leading Atypical Antipsychotic Drugs from a Leading US Pharmacy
Table 7.3 Prices of The Leading Atypical Antipsychotic Drugs from a Leading US Pharmacy (continued)
Table 7.4 Direct to Consumer Advertising (DTC) Expenditure in the Schizophrenia Market
Table 8.1 Pre-clinical Development
Table 8.2 Phase I Clinical Trials
Table 8.3 Phase II Clinical Trials
Table 8.4 Phase III Clinical Trials
Table 8.5 Line Extensions and Extended Approval for Some of the Leading Drugs (July 2005)
Table 9.1 The Relative Strengths and Weaknesses of the Leading Schizophrenia Drugs with a Prediction of their Future Sales Potential
Figures Included in this Report
Figure 3.1 Sales of Leading Psychotherapeutic Agents in 2004 by Main Indication
Figure 3.2 Revenues from the Leading Schizophrenia Drugs in 2004
Figure 3.3 Percentage Growth in Revenues from 2003-2004 for the Leading Drugs
Figure 3.4 Percentage Market Shares for the Leading Drugs for Schizophrenia in 2004
Figure 4.1 A SWOT Chart for the Schizophrenia Market
Figure 5.1 Total World Revenues ($m) for Schizophrenia Treatments 2004-2010
Figure 5.2 Growth Rates (%) for Schizophrenia Treatments 2004-2010
Figure 5.3 World Revenues ($m) by Drug for Schizophrenia Treatments 2004-2010
Figure 5.4 World Revenues ($m) by Drug for Schizophrenia Treatments 2004-2010
Figure 5.5 World Revenues ($m) for Schizophrenia Treatments 2004 and 2010 Compared
Figure 5.6 Change in World Revenue ($m), 2004 and 2010 Compared
Figure 5.7 World Market Share for the Leading Drugs in 2004
Figure 5.8 World Market Share for the Leading Drugs in 2010
Figure 5.9 World Market Share 2004 compared with 2010
Figure 5.10 Change in World Market (%) Share 2004 to 2010
Figure 5.11 World Growth Rate for Zyprexa 2004-2010
Figure 5.12 World Growth Rate for Risperdal 2004-2010
Figure 5.13 World Growth Rate for Seroquel 2004-2010
Figure 5.14 World Growth Rate for Abilify 2004-2010
Figure 5.15 World Growth Rate for Geodon 2004-2010
Figure 5.16 World Growth Rate for Clozaril 2004-2010
Figure 6.1 Market Share (%) for Schizophrenia by Country and Region
Figure 6.2 Revenues ($m) for Schizophrenia by Country and Region
Figure 7.1 A Comparison of the Atypical Antipsychotics via Perceptual Mapping
Companies Mentioned in this Report
Acadia Pharmaceuticals
Akzo Nobel
Astellas Pharma
AstraZeneca
Barr Pharmaceuticals
Bioline Rx
Bristol-Myers Squibb
Cortex Pharmaceuticals
Creighton Products Corporation
Dainippon
Dr. Reddy's Laboratories
Egis-Gyogyszergyar
Elan Corporation
Eli Lilly
Forest Laboratories
Fujisawa Pharmaceutical
Geneva Pharmaceuticals
GlaxoSmithKline
Guilford Pharmaceuticals
H. Lundbeck A/S
Hoffmann-La Roche
Ivax Corporation
Janssen Pharmaceutica Products LP
Johnson & Johnson & Johnson
MedAdNews
Memory Pharmaceuticals Corporation
Merck & Co
Mylan Laboratories
Novartis
NPS Allelix Corporation
NPS Pharmaceuticals
Organon
Otsuka Pharmaceutical
Pfizer
Repligen Corporation
Ricerca Biosciences LLC
Saegis Pharmaceuticals
Sandoz Pharmaceuticals
Sanofi-Aventis
Sanofi-Synthelabo
Shire Pharmaceuticals
SK Corporation
Solvay Pharmaceuticals
Spectrum Pharmaceuticals
Targacept
Teva Pharmaceutical Industries
Vanda Pharmaceuticals
visiongain
Wyeth Pharmaceuticals
Zenith Goldline Pharmaceutical
The schizophrenia world market generated total revenues of nearly $12 billion in 2004. The market is growing now. Are you capitalising on this market? Did you benefit from the strong growth in 2003 and 2004? With almost all the leading drugs also approved for treating aspects of bipolar disorder, the opportunities for drugs in this market are increasing rapidly. Dementia, autism, aggression, post-traumatic stress disorder and severe depression - the unapproved (off-label) uses for some of the drugs offer improved sales options. Ensure you benefit today by reading visiongain's unique report.
This market report delivers to you exactly how schizophrenia treatments will develop this decade. You will receive analytical forecasts of the market from 2005 to 2010. This executive report presents you with financial forecasting, SWOT analysis and perceptual mapping applied specifically to the schizophrenia drug market.
In particular, the report concentrates on the following areas:
The current state of the market for atypical antipsychotic drugs in the treatment of schizophrenia
Drivers and opportunities in the schizophrenia market
Restraints and threats in the schizophrenia market
How the schizophrenia market is likely to grow between 2005 and 2010
Prospects for the current market leading drugs between 2005 and 2010
The potential for generics manufacturers to penetrate the market further
A breakdown of the schizophrenia market by country and region
A discussion of unmet needs in the schizophrenia market
Detailed information on pipeline products and line extensions in this market, with an analysis of the prospects for those agents
The schizophrenia market is dominated by 6 drugs marketed by 8 companies:
Eli Lilly's Zyprexa
Johnson & Johnson's Risperdal
AstraZeneca and Fujisawa Pharmaceutical's Seroquel
Bristol-Myers Squibb and Otsuka Pharmaceutical's Abilify
Pfizer's Geodon
Novartis' Clozaril/Leponex
With continued prospects for high revenue generation and market growth, this market demands your attention. Nevertheless, the schizophrenia market is facing great challenges in terms of clinical performance, competition, regulatory restraints and legal challenges. Given the complexity of schizophrenia, continued investment in research and development of improved treatments is required, as well as research into the causes and mechanisms of the disorder - this is costly and time-consuming. However recent developments in both the pharmaceutical industry and the public sector provide scope for optimism - understand these crucial issues today.
Why You Should Buy This Report
Visiongain's report pays particular attention to revenues, growth rates and market shares for schizophrenia treatments. It discusses the forces that influence the schizophrenia market, especially its competitive characteristics, drivers and restraints. With unique insight the report offers the strengths, weaknesses, opportunities and threats of individual products.
A key chapter forecasts the performance of the current leading drugs until 2010. Visiongain's in-house analytical assessment of future revenues, growth rates and relative market shares are available to you in one easy to read format. Various quantitative and qualitative methods are used, with the relevant issues discussed fully for you.
Plus, the report also includes a breakdown of the world market for atypical antipsychotic drugs into countries and regions, including relevant statistics on spending across the world. Importantly, the report discusses pipeline developments for treating schizophrenia comprehensively in the future. The market appears to be entering an exciting new phase, with both established market leaders and potential new entrants having products in mid-to-late stage development - you should be part of this market.
Table of Contents
1. Executive Summary
2. Introduction to Schizophrenia
2.1 Symptoms of the Condition
2.2 Diagnosis of Schizophrenia
2.3 Links with Other Disorders
2.4 Epidemiology of Schizophrenia
2.5 Causes and Physiological Characteristics of Schizophrenia
2.6 The Treatment of Schizophrenia by Drugs
2.7 Other Aspects of Treating or Managing Schizophrenia
2.8 Mechanisms of the Newer Therapeutic Agents - The Atypical Antipsychotics
2.9 An Overview of How the Typical Antipsychotic Drugs Differ from the Atypical Antipsychotics
2.10 Adherence by Schizophrenics is Often Low
2.11 Off-Label Prescription Extending Approved Indications for Atypical Antipsychotic Drugs
2.12 The Prospects for Patients
3. The World Market 2003-2004 for Anti-Schizophrenic Drugs
3.1 The Market for Treating Schizophrenia Contains Three Major Blockbusters
3.2. Eli Lilly's Zyprexa Led the Schizophrenia Market in 2004
3.3 The Other Atypical Antipsychotics Displayed Healthy Revenues in 2004
3.3.1 Johnson & Johnson's Risperdal - Second Largest Revenue Generator in Market
3.3.2 AstraZeneca's Seroquel - Maintaining a Strong Position
3.3.3 Otsuka Pharmaceutical & Bristol-Myers Squibb's Abilify Shows Enormous Potential
3.3.4 Pfizer's Geodon - A Promising Start
3.3.5 Novartis' Clozaril/Leponex - The Pioneering Atypical Antipsychotic
3.4 The Atypical Antipsychotic Drugs Still Suffer from Concerns Over Side Effects
3.5 Patent Expiry Among the Leading Schizophrenia Drugs - An Increasing Threat 2005-2010
3.6 Comparative Studies on Schizophrenia Drugs - a Blessing or a Curse for the Market Leaders?
4. An Analysis of Factors that Influence the Schizophrenia Market
4.1 SWOT Analysis of the Schizophrenia Market?
4.2 What Are the Main Drivers, Strengths and Opportunities in the Schizophrenia Market?
4.3 Principal Drivers in the Schizophrenia Market
4.4 The Atypical Antipsychotics Constitute a Large, High-Growth Market
4.5 Maintaining High Revenue Generation in Spite of Challenges
4.6 There is Scope for Greater Penetration into Related Markets
4.7 Advances in Technology Likely to Bring Benefits to the Market
4.8 Comparative Studies - a Two Edged Sword
4.9 The Principal Restraints in the Schizophrenia Market
4.10 Risk of Diabetes and Other Serious Side Effects with the Atypical Antipsychotic Drugs
4.11 Concerns Over the High Price of the Treatments - Who Yields the Power?
4.12 A Discussion of Generic Drugs in This Market - How Great is Their Threat?
5. The World Market for Schizophrenia Treatments 2004-2010
5.1 World Revenue from 2004 to 2010 - A Maturing Market with High Revenue Potential
5.2 Zyprexa to Retain Market Leadership Despite Pressures
5.3 Risperdal - Strong Revenue Potential Despite Side Effects and Generics Threat
5.4 Will Seroquel Remain a Strong Contender?
5.5 Can Abilify Build upon Early Promise?
5.6 Geodon has Growth Potential Despite Generics Threat
5.7 Can Clozaril ''Re-Invent'' Itself to Offset Decline?
6. A Geographical Breakdown of the World Market
6.1 Schizophrenia - A World Market Led by US Sales
6.2 The US Leads the World in Healthcare Spending
6.3 The US and Europe are the Most Important Markets for Schizophrenia Treatments
7. An Analysis of Unmet Needs in the Schizophrenia Market
7.1 Analysing Efficacy, Safety and Tolerability in the Schizophrenia Market via Perceptual Mapping
7.2 How Much Scope is There to Improve Efficacy in Schizophrenia Drugs?
7.3 How Much Scope is There to Improve Safety and Tolerability in Schizophrenia Drugs?
7.4 Pricing of the Atypical Antipsychotics - Close Scrutiny by Medical Authorities and Concern Amongst Patients' Groups
7.5 Screening and Diagnosis by Healthcare Services is a Necessary Prerequisite for Market Growth
7.6 Direct Advertising - An Opportunity to Educate Consumers but also a Source of Controversy
8. Pipeline Drugs for Schizophrenia
8.1 Agents in Preclinical Development
8.1.1 BL-1020
8.1.2 Other Agents in Preclinical Development
8.2 Agents in Phase I of Clinical Development
8.2.1 TC-1827
8.2.2 Other Agents in Phase I Clinical Development
8.3 Agents in Phase II of Clinical Development
8.3.1 Talnetant
8.3.2 SM13496 (Lurasidone)
8.3.3 ACP-103
8.3.4 ACP-104
8.3.5 Org 24448
8.3.6 Other Agents in Phase II Clinical Development
8.4 Agents in Phase III of Clinical Development
8.4.1 Iloperidone
8.4.2 Asenapine
8.4.3 Bifeprunox
8.4.4 Blonanserin
8.4.5 Paliperidone
8.4.6 Osanetant
8.4.7 Other Agents in Phase III Clinical Development
8.5 Treatments Recently Approved for Treating Schizophrenia
8.5.1 Serdolect
8.6 The Further Development of Existing Treatments for Schizophrenia
8.6.1 A Line Extension of AstraZeneca's Seroquel
8.7 An Overall Assessment of Pipeline Developments for the Schizophrenia Market
9 Conclusions of this Market Study
Tables Included in this Report
Table 1.1 Market Leading Drugs for Treating Schizophrenia
Table 2.1 First Generation Antipsychotic Drugs for Treating Schizophrenia (the Typical Antipsychotics)
Table 2.2 Mild and Serious Side Effects of First Generation Antipsychotics
Table 2.3 Second Generation Antipsychotic Drugs for Treating Schizophrenia (the Atypical Antipsychotics)
Table 2.4 Mild and Serious Side Effects of Second Generation Antipsychotics
Table 3.1 Best-Selling Drugs in the Therapeutic Category Psychotherapeutic Agents in 2004
Table 3.2 The Leading Drugs for Treating Schizophrenia: Indications and Modes of Action
Table 3.3 The Leading Drugs for Treating Schizophrenia: 2004 Revenues and Growth Rates
Table 3.4 Market Shares for the Leading Schizophrenia Drugs in 2004
Table 3.5 Side Effects and Potential Risks Associated with Leading Drugs for Schizophrenia
Table 3.6 Patent Expiry in the Market Leading Drugs for Schizophrenia
Table 4.1 Side Effect Profiles of the Second Generation Antipsychotic Drugs
Table 5.1 World Revenues ($m) for the Leading Schizophrenia Drugs 2004 to 2010
Table 5.2 Compound Annual Growth Rates (CAGRs) for the Leading Schizophrenia Drugs
Table 5.3 World Revenues ($m) of Seroquel and Abilify Only, 2004-2010
Table 5.4 World Revenues for Schizophrenia Treatments, 2004 and 2010 Compared
Table 5.5 Market Share (%) for Schizophrenia Drugs, 2004 and 2010 Compared
Table 6.1 A Global Breakdown of the Schizophrenia Market by Country and Region, 2004
Table 6.2 Total Health Spending ($) and Drug Expenditure per Patient in Major Countries in 2002
Table 6.3 Annual Average Growth Rates (%) in GDP, Total and Public Health Expenditure of Principal Countries, 1997-2002
Table 7.1 Efficacy and Side Effect Profiles of the Leading Schizophrenia Drugs
Table 7.2 Prices of The Leading Atypical Antipsychotic Drugs from a Leading US Pharmacy
Table 7.3 Prices of The Leading Atypical Antipsychotic Drugs from a Leading US Pharmacy (continued)
Table 7.4 Direct to Consumer Advertising (DTC) Expenditure in the Schizophrenia Market
Table 8.1 Pre-clinical Development
Table 8.2 Phase I Clinical Trials
Table 8.3 Phase II Clinical Trials
Table 8.4 Phase III Clinical Trials
Table 8.5 Line Extensions and Extended Approval for Some of the Leading Drugs (July 2005)
Table 9.1 The Relative Strengths and Weaknesses of the Leading Schizophrenia Drugs with a Prediction of their Future Sales Potential
Figures Included in this Report
Figure 3.1 Sales of Leading Psychotherapeutic Agents in 2004 by Main Indication
Figure 3.2 Revenues from the Leading Schizophrenia Drugs in 2004
Figure 3.3 Percentage Growth in Revenues from 2003-2004 for the Leading Drugs
Figure 3.4 Percentage Market Shares for the Leading Drugs for Schizophrenia in 2004
Figure 4.1 A SWOT Chart for the Schizophrenia Market
Figure 5.1 Total World Revenues ($m) for Schizophrenia Treatments 2004-2010
Figure 5.2 Growth Rates (%) for Schizophrenia Treatments 2004-2010
Figure 5.3 World Revenues ($m) by Drug for Schizophrenia Treatments 2004-2010
Figure 5.4 World Revenues ($m) by Drug for Schizophrenia Treatments 2004-2010
Figure 5.5 World Revenues ($m) for Schizophrenia Treatments 2004 and 2010 Compared
Figure 5.6 Change in World Revenue ($m), 2004 and 2010 Compared
Figure 5.7 World Market Share for the Leading Drugs in 2004
Figure 5.8 World Market Share for the Leading Drugs in 2010
Figure 5.9 World Market Share 2004 compared with 2010
Figure 5.10 Change in World Market (%) Share 2004 to 2010
Figure 5.11 World Growth Rate for Zyprexa 2004-2010
Figure 5.12 World Growth Rate for Risperdal 2004-2010
Figure 5.13 World Growth Rate for Seroquel 2004-2010
Figure 5.14 World Growth Rate for Abilify 2004-2010
Figure 5.15 World Growth Rate for Geodon 2004-2010
Figure 5.16 World Growth Rate for Clozaril 2004-2010
Figure 6.1 Market Share (%) for Schizophrenia by Country and Region
Figure 6.2 Revenues ($m) for Schizophrenia by Country and Region
Figure 7.1 A Comparison of the Atypical Antipsychotics via Perceptual Mapping
Companies Mentioned in this Report
Acadia Pharmaceuticals
Akzo Nobel
Astellas Pharma
AstraZeneca
Barr Pharmaceuticals
Bioline Rx
Bristol-Myers Squibb
Cortex Pharmaceuticals
Creighton Products Corporation
Dainippon
Dr. Reddy's Laboratories
Egis-Gyogyszergyar
Elan Corporation
Eli Lilly
Forest Laboratories
Fujisawa Pharmaceutical
Geneva Pharmaceuticals
GlaxoSmithKline
Guilford Pharmaceuticals
H. Lundbeck A/S
Hoffmann-La Roche
Ivax Corporation
Janssen Pharmaceutica Products LP
Johnson & Johnson & Johnson
MedAdNews
Memory Pharmaceuticals Corporation
Merck & Co
Mylan Laboratories
Novartis
NPS Allelix Corporation
NPS Pharmaceuticals
Organon
Otsuka Pharmaceutical
Pfizer
Repligen Corporation
Ricerca Biosciences LLC
Saegis Pharmaceuticals
Sandoz Pharmaceuticals
Sanofi-Aventis
Sanofi-Synthelabo
Shire Pharmaceuticals
SK Corporation
Solvay Pharmaceuticals
Spectrum Pharmaceuticals
Targacept
Teva Pharmaceutical Industries
Vanda Pharmaceuticals
visiongain
Wyeth Pharmaceuticals
Zenith Goldline Pharmaceutical